Clicky

Protagonist Therapeutics, Inc.(PTGX) News

Date Title
Jul 21 Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
Jul 14 Exploring 3 High Growth Tech Stocks In The US Market
Jun 30 Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
Jun 30 Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
Jun 26 Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Jun 24 Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
Jun 20 Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
May 27 Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome
May 21 Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Apr 16 Protagonist Therapeutics Reports Granting of Inducement Award
Apr 10 Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
Mar 15 Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?
Mar 13 Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
Mar 12 Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why
Mar 11 PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
Mar 11 Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success
Mar 11 J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
Mar 11 Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday
Mar 10 Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Mar 10 Sector Update: Health Care Stocks Decline Late Afternoon